Werlinich Asset Management LLC Increases Position in Pfizer Inc. (NYSE:PFE)

Werlinich Asset Management LLC grew its stake in Pfizer Inc. (NYSE:PFEFree Report) by 11.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,810 shares of the biopharmaceutical company’s stock after acquiring an additional 9,063 shares during the quarter. Pfizer comprises about 1.6% of Werlinich Asset Management LLC’s portfolio, making the stock its 20th biggest position. Werlinich Asset Management LLC’s holdings in Pfizer were worth $2,467,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Sanders Morris Harris LLC acquired a new stake in shares of Pfizer in the 1st quarter worth $408,000. MJP Associates Inc. ADV boosted its position in shares of Pfizer by 16.5% in the 1st quarter. MJP Associates Inc. ADV now owns 16,142 shares of the biopharmaceutical company’s stock worth $448,000 after purchasing an additional 2,285 shares in the last quarter. Hummer Financial Advisory Services Inc boosted its position in shares of Pfizer by 6.8% in the 1st quarter. Hummer Financial Advisory Services Inc now owns 7,886 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 500 shares in the last quarter. Executive Wealth Group LLC acquired a new stake in Pfizer during the 1st quarter worth about $277,000. Finally, Rockland Trust Co. lifted its position in Pfizer by 3.3% during the 1st quarter. Rockland Trust Co. now owns 404,330 shares of the biopharmaceutical company’s stock worth $11,220,000 after acquiring an additional 12,931 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, June 17th. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $35.86.

View Our Latest Analysis on PFE

Pfizer Stock Performance

Shares of PFE stock remained flat at $27.74 during trading hours on Friday. The stock had a trading volume of 52,561,555 shares, compared to its average volume of 30,487,030. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $38.99. The firm has a market cap of $157.19 billion, a P/E ratio of -462.26, a price-to-earnings-growth ratio of 1.09 and a beta of 0.70. The stock has a 50-day simple moving average of $27.67 and a two-hundred day simple moving average of $27.71. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period last year, the firm earned $1.23 earnings per share. On average, analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.06%. The ex-dividend date of this dividend was Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.